drugset / Trial / NCT04284293
CNS10-NPC for the Treatment of RP
Phase 1
Active not recruiting
16 enrolled
Cedars-Sinai Medical Center
California Institute for Regenerative Medicine (CIRM) · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The investigator is examining the safety of transplanting cells into the subretinal space of patients with Retinitis Pigmentosa (RP). The cells are called neural progenitor cells, which are a type of stem cell that can become several different types of cells in the nervous system. These cells have been derived to specifically become astrocytes, which is a type of neuronal cell. The cells are called "CNS10-NPC." The investigational treatment has been tested in animals, but it has not yet been tested in people. In this study, the investigators want to learn if CNS10-NPC cells are safe to transplant into the subretinal space of people.
Timeline
- Start
- 2021-07-22
- Primary completion
- 2026-07
- Completion
- 2026-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CNS10-NPC | Unknown | 300000 cells | Other |
| Subject | CNS10-NPC | Unknown | 1e+06 cells | Other |